🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to scientists.

A Worldwide Challenge

The sexually transmitted infection are on the rise worldwide, with data suggesting in excess of 82 million new cases per year. Particularly high rates are reported in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, escalating drug resistance and the very limited treatment choices currently available.”

Public health authorities are particularly alarmed about the surge in drug-resistant strains. The World Health Organization has classified it as a "critical concern". Ongoing monitoring found that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Receive Clearance

Zoliflodacin, also known as Nuzolvence, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Experts hope that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the drugmaker GSK, gained clearance in concurrent days. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to see it through.

“This approval signifies a huge turning point in the therapy of superbug gonorrhoea, which until now has been staying ahead of antibiotic development.”

Testing Data and Global Access

As per results released by a prominent scientific publication, the new drug successfully treated over nine in ten of cases of the STI. This establishes an equal footing with the typical regimen, which uses a dual-drug approach. The study included over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians treating patients have shared optimism. Having a easy-to-administer therapy of this kind is seen as a "critical tool" for public health efforts. This is viewed as essential to lessen the impact of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.